RespireRx Pharmaceuticals Inc. to Present at BIO CEO & Investor Conference 2017
CEO to review dronabinol, a Phase 3-ready medicine for the treatment of obstructive sleep apnea, and provide pipeline update Glen Rock, N.J., Feb. 10, 2017/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTC QB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for the treatment of respiratory disorders for which there are no…
RespireRx Pharmaceuticals Inc. to Present at 9th Annual Biotech Showcase™ 2017
CEO to Review Completed Phase 2B Dronabinol Clinical Trial for the Treatment of Obstructive Sleep Apnea and Provide Pipeline Update Glen Rock, N.J., Jan. 6, 2017/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for the treatment of respiratory disorders, particularly sleep apneas and drug-induced…
RespireRx Pharmaceuticals Inc. Announces Positive Results from Phase 2B PACE Study Conducted by the University of Illinois Dronabinol Reduces Symptoms of Obstructive Sleep Apnea
Glen Rock, N.J., December 23, 2016 /Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce positive results of the PACE (Pharmacotherapy of Apnea by Cannabimimetic Enhancement) trial conducted by Dr. David Carley and colleagues at the University of Illinois at Chicago and Northwestern University. The PACE trial, a…
RespireRx Pharmaceuticals Inc. Announces Data for CX1739 Clinical Study in Opioid Induced Respiratory Depression
Glen Rock, N.J., December 15, 2016 /Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression announces data for its CX1739 clinical study in opioid induced respiratory depression. Comments by the Executive Chairman and Chief Scientific…